Semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic medications.

The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss medications Ozempic and Wegovy was linked with a near halving of reported pain ...

Westend61/Getty Images The use of GLP-1 medications such as semaglutide — more widely known under the ... “I think if ...

Dr Lotte Knudson, a scientist from Copenhagen, revolutionized research into drugs used by millions to lose weight. She has ...

A clinical trial funded by Novo Nordisk found that Ozempic (semaglutide) was linked with reduced pain among patients with ...

Researchers have discovered that semaglutide weight loss drugs like Ozempic may reduce the risk of early-onset colorectal cancer (CRC) in diabetes patients.

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Semaglutide was linked to a significantly reduced risk, most strongly compared with insulin and most weakly with other GLP-1 RAs.

Semaglutide, the weight management drug sold as Ozempic and Wegovy, may reduce the risk of Alzheimer's disease by 40% to 70% ...

In this week’s Bloom Boost – health news you might have missed, Gayle Guyardo , the host of the nationally syndicated health ...

Novo Nordisk said on Friday its weight-loss drug Wegovy met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis.